Heteroaryl pyridone and aza-pyridone compounds

A method of treating a disease or disorder which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of a Formula I compound and a pharmaceutically acceptable carrier, glidant, diluent, or excipient to a patient with a disease or disorder selected from immune disorders, cancer, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders,

• wherein the Formula I compound has the structure:
• or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein:
• X1 is CR1 or N;
• X2 is CR2 or N;
• X3 is CR3 or N;
• where one or two of X1, X2, and X3 are N;
• R1, R2 and R3 are independently selected from H, F, Cl, —NH2, —NHCH3, —N(CH3)2, —OH, —OCH3, —OCH2CH3, —OCH2CH2OH, and C1-C3 alkyl;
• R4 is selected from H, F, Cl, CN, —CH2OH, —CH(CH3)OH, —C(CH3)2OH, —CH(CF3)OH, —CH2F, —CHF2, —CH2CHF2, —CF3, —C(O)NH2, —C(O)NHCH3, —C(O)N(CH3)2, —NH2, —NHCH3, —N(CH3)2, —NHC(O)CH3, —OH, —OCH3, —OCH2CH3, —OCH2CH2OH, cyclopropyl, cyclopropylmethyl, 1-hydroxycyclopropyl, imidazolyl, pyrazolyl, 3-hydroxy-oxetan-3-yl, oxetan-3-yl, and azetidin-1-yl;
• R5 is optionally substituted C6-C20 aryl, C3-C12 carbocyclyl, C2-C20 heterocyclyl, C1-C20 heteroaryl, —(C6-C20 aryl)-(C2-C20 heterocyclyl), —(C1-C20 heteroaryl)-(C2-C20 heterocyclyl), —(C1-C20 heteroaryl)-(C2-C20 heterocyclyl)-(C2-C20 heterocyclyl), —(C1-C20 heteroaryl)-(C2-C20 heterocyclyl)-(C1-C6 alkyl), —(C1-C20 heteroaryl)-(C1-C6 alkyl), —(C2-C20 heterocyclyl)-(C1-C6 alkyl), —(C2-C20 heterocyclyl)-(C3-C12 carbocyclyl), —(C1-C20 heteroaryl)-(C3-C12 carbocyclyl), or —(C1-C20 heteroaryl)-C(═O)—(C2-C20 heterocyclyl);
• R6 is H, —CH3, —CH2CH3, —CH2CH2OH, —CHF2, —NH2, or —OH;
• R7 is selected from the structures:
• where the wavy line indicates the site of attachment;
• and
• Y1 and Y2 are independently selected from CH and N, where Y1 and Y2 are not each N;
• where alkyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl are optionally substituted with one or more groups independently selected from F, Cl, Br, I, —CN, —CH3, —CH2CH3, —CH(CH3)2, —CH2CH(CH3)2, —CH2OH, —CH2OCH3, —CH2CH2OH, —C(CH3)2OH, —CH(OH)CH(CH3)2, —C(CH3)2CH2OH, —CH2CH2SO2CH3, —CH2OP(O)(OH)2, —CH2F, —CHF2, —CF3, —CH2CF3, —CH2CHF2, —CH(CH3)CN, —C(CH3)2CN, —CH2CN, —CO2H, —COCH3, —CO2CH3, —CO2C(CH3)3, —COCH(OH)CH3, —CONH2, —CONHCH3, —CON(CH3)2, —C(CH3)2CONH2, —NH2, —NHCH3, —N(CH3)2, —NHCOCH3, —N(CH3)COCH3, —NHS(O)2CH3, —N(CH3)C(CH3)2CONH2, —N(CH3)CH2CH2S(O)2CH3, —NO2, ═O, —OH, —OCH3, —OCH2CH3, —OCH2CH2OCH3, —OCH2CH2OH, —OCH2CH2N(CH3)2, —OP(O)(OH)2, —S(O)2N(CH3)2, —SCH3, —S(O)2CH3, —S(O)3H, cyclopropyl, oxetanyl, azetidinyl, 1-methylazetidin-3-yl)oxy, N-methyl-N-oxetan-3-ylamino, azetidin-1-ylmethyl, and morpholino.